Press release
Malmö, 29 may, 2017
Acarix CADScor®System – an advanced, easy-to-use initially test to rule out coronary artery disease with high accuracy.
Displayed at the British Cardiovascular Society Annual Meeting in Manchester, 5-7 June.
In preparation for the launch appears in the Swedish/Danish Acarix AB:s (publ) (“Acarix”) CADScor®System up at the British Cardiovascular Society Annual Meeting in Manchester, 5-7 June. Delegates will be able to take part of the results from a study presented at the American College of Cardiology’s annual scientific meeting in Washington, dc, 17 – 19 march, 2017 which showed that CADScor ®System, which is a non-invasive test to rule out coronary artery disease with 97% negative predictive value. According to the British Heart Foundation responds heart disease for about 26% of all deaths in the united kingdom, or 116,000 cases per year. Early diagnosis is a priority, therefore high of british health the NHS.
If the study
The current study was led by Morten Böttcher, MD PhD FESC (responsible researcher) and Simon Winther, MD PhD at the Department of cardiology, Aarhus university Hospital, Denmark: “Despite access to improved algorithms for riskstratifiering is the use of established surveys, such as nuclear stress test or CT continued to be extensive. We tested, therefore, the diagnostic accuracy of the CADScor®Systems for the exclusion of CAD in order to see if it could be used to reduce the demand for more advanced diagnostic methods. We have come to the conclusion that, with its ability to exclude CAD with a 97% negative predictive value, can this advanced, easy-to-use, stetoskopliknande instrument may be used as an initial test.”
Acarix CEO Søren Rysholt Christiansen commented:
“We are very pleased with the results of the study and is now preparing for the launch of the instrument. Coronary artery disease constitutes a significant problem in the Uk and affects more than 120 million people worldwide, but the current forms of diagnostics which can easily escalate to include expensive investigations in the form of imaging and coronary angiography can be significantly improved. If the method is introduced can CADScor®Systems offer a quick, initial test that could lead to improved triage, i.e. to patients who need further testing are referred to such, and that patients with symptoms due to other causes than coronary heart disease do not need to be tested further.
If CADScor®System
The portable CADScor®System uses ultra-sensitive phonokardiografi combined with advanced electronics and algorithms to exclude CAD with a 97% negative predictive value. Measurement with CADScor®System is fast, non-invasive and strålningsfri and can be performed in the usual clinical setting in less than 10 minutes.
Patients with suspected coronary artery disease examined today with one or several methods, including stress tests, nuclear medicine studies, and invasive coronary angiography. In many cases, patients are either healthy or not in need of treatment. The new CADScor®System is intended as a first, quick and non-invasive test and by CAD can be excluded at an early stage improved diagnosprocessen.
CADScor®System to be displayed in booth # 17 at the British Cardiovascular Society Annual Meeting in Manchester.
Contact:
Acarix AB
Søren Rysholt Christiansen, CEO E-mail: dksrc@acarix.com Telephone: +45 2777 1112
To the editors:
Acarix, CADScor®System and the measurement of heart sounds
Acarix was founded in 2009 and since 2010, the Danish venture capital companies, Seed Capital (DK) and Sunstone Life Science Ventures (DK) stood behind the development of the company towards the introduction on the market. Acarix has also strengthened its management team with new people with experience from senior positions within the international medtech company – the CEO Søren Rysholt Christiansen previously worked at ELOS Medtech, GN ReSound and Cook Medical.
Acarix CADScor®System is based on cutting-edge research in the ljuddetektion and signalprocess. It has long been known that both the heart’s contraction and turbulent blood flow gives rise to sound. Kontraktionsrelaterade sound occurs in the lower frequencies, while the turbulent sounds of blood flow (caused by partial obstruction (stenosis) in the kransartärerna) causes a sound of higher frequency. The detection of these murmurs require devices with high sensitivity because the energy of the murmur is very weak. To detect and register the murmur arising from the coronary arteries requires not only an advanced sensor, but also that the detector placement on the skin over the heart is such that the recorded signal is optimized and that the external noise is avoided.
Acarix CADScor®System is built as an all-in-one system comprehensive recording of blåsljuden, signal processing and presentation of p.k. patient-specific CAD-score, on the device’s screen. CADScor®System also includes the necessary electronics to instruct the staff and guide the patient through the mätperioderna directly on the screen. The system also includes a docking station for daily testing and calibration of the sensor. The system is integrated with an adhesive plate that locks the CADScor®sensor in a fixed position above the heart during the measurement.
The software in the Acarix CADScor®System ensures that the recording always takes place under controlled conditions.
CADScor®System is CE-certified (by TÜV 2015). Commercial launch is scheduled in Q2 2017.
See more at www.acarix.com. Press kit: http://www.acarix.com/about-us/press-downloads/.
20170529 Press release British Cardiolovascular Society_SE